Clinical Trial

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study trial is a open-label, single-arm, multicenter phase II trial investigating the combined treatment of atezolizumab and derazantinib in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-12-13; most recent amendment 2025-11-27.
Status change: Recruiting → Active, Not Recruiting 2024-07-22
Status change: Not Yet Recruiting → Recruiting 2022-03-29
Trial Details
NCT Number NCT05174650
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Conditions Intrahepatic Cholangiocarcinoma
Enrollment 27 participants
Start Date 2022-04-20
Primary Completion 2025-12 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-12-05